Condition
Meningioma, Malignant
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Recruiting2
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06275919Phase 2RecruitingPrimary
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06557512Not ApplicableRecruiting
Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
NCT04728568Not ApplicableUnknownPrimary
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
Showing all 3 trials